C Platform held an 'AI-based pharma, biotech and healthcare R&D acceleration strategy seminar' with HPE, W&B (Weights & Biases Korea) and NovaDX.

At the seminar, C Platform presented ways to flexibly use AI infrastructure and MLOps platforms to fit customers' research environments and operational objectives. It stressed this as a key option to raise the return on investment from AI adoption.

W&B introduced an MLOps and LLMOps platform that supports AI R&D operations. The W&B platform integrates management of the full process, including experiment tracking, data and model version control, and building collaborative environments. It supports moving AI research with many repeat experiments into real operating environments.

HPE presented a high-performance GPU-based infrastructure strategy optimised for large-scale AI model training and inference. It introduced ways to build integrated infrastructure that supports the full AI lifecycle, from data processing to model training, inference and operations, based on an architecture with scalability and stability.

NovaDX introduced a customer-tailored integrated adoption service, from AI infrastructure design to configuring MLOps environments.

Hyun-seok Kim (김현석), head of W&B Korea, said, "W&B is a platform used like a standard by LLM development organisations worldwide, and South Korea is a key market that ranks in the top 3 globally in usage." He added, "Going forward, corporate AI competitiveness depends not just on model performance itself, but on the capability to systematically manage experiments and data and apply them quickly to operational environments."

Hyun-beom Baek (백현범), head of division at C Platform, said, "In the pharma and biotech industry, AI is no longer about whether to adopt it. The operating system that connects it to actual results is core competitiveness." He added, "Based on a global partner ecosystem including HPE and W&B, C Platform will take the lead in building an AI R&D execution framework that customers can tangibly feel."